Home Tags CMO

Tag: CMO

Antibody-Drug Conjugates: Manufacturing Challenges and Trends

Antibody-drug conjugates (ADCs), a form of Immuno-conjugate or bio-conjugate, are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells....

How can Single-use Bioprocessing Technologies Tackle Current Bottlenecks?

Traditional systemic administration of chemotherapeutic agents does not differentiate between healthy and diseased tissue. Antibody-drug conjugates (ADCs) are highly efficacious drugs with lower side...

Contract Manufacturing of Antibody-drug Conjugates – A Growing Market

The demand for manufacturing capacity of antibody-drug conjugates (ADCs), which includes a highly potent cytotoxic drug linked to a monoclonal antibody and have shown to...

Novasep Expands It’s North American Facility: Adding A Synthesis Laboratory...

Lyon (France) -based Novasep, a leading supplier of services and technologies for the life sciences industry is building a new synthesis laboratory and a...

CPhI Worldwide 2015, Antibody-drug Conjugates and Market Progression

Ahead of CPhI Worldwide 2015, CPhI expert panelist, Vivek Sharma, CEO of Pharma Solutions at Piramal, analyses the challenges in developing and manufacturing of...

Novasep Reinforces Bioconjugation Services with €10M Investment

Novasep (Pompey, France), a global provider of cost-effective and sustainable manufacturing services and technologies for life sciences molecules and fine chemicals will build a...
BT-062-Multiple-Myeloma-BIOTEST

Report Presents Latest Development in CMO Market for ADCs

While the basic concept of Antibody-drug Conjugates (ADCs), a new class of biopharmaceutical drugs designed as a targeted therapy, is quite simple - a biological active cytotoxic or chemotherapy drug, is delivered to the target tissue through linking it with a monoclonal antibody - the practical challenge of manufacturing such complex and highly toxic molecules is huge.

FEATURED RESOURCES